WallStreetZenWallStreetZen

NASDAQ: TRVI
Trevi Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for TRVI

Based on 2 analysts offering 12 month price targets for Trevi Therapeutics Inc.
Min Forecast
$8.00+201.89%
Avg Forecast
$8.50+220.75%
Max Forecast
$9.00+239.62%

Should I buy or sell TRVI stock?

Based on 2 analysts offering ratings for Trevi Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TRVI stock forecasts and price targets.

TRVI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-09
lockedlocked$00.00+00.00%2024-03-21

1 of 1

Forecast return on equity

Is TRVI forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is TRVI forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

TRVI revenue forecast

What is TRVI's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$5.1M
Avg 2 year Forecast
$31.7M
Avg 3 year Forecast
$100.1M

TRVI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRVI$2.65$8.50+220.75%Buy
CRDF$4.18$10.50+151.20%Strong Buy
CADL$6.05$11.00+81.82%Buy
ATOS$1.50$4.00+166.67%Buy
KOD$3.38$3.33-1.39%Strong Sell
View Top Biotech Stocks

Trevi Therapeutics Stock Forecast FAQ

Is Trevi Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TRVI) stock is to Buy TRVI stock.

Out of 2 analysts, 0 (0%) are recommending TRVI as a Strong Buy, 2 (100%) are recommending TRVI as a Buy, 0 (0%) are recommending TRVI as a Hold, 0 (0%) are recommending TRVI as a Sell, and 0 (0%) are recommending TRVI as a Strong Sell.

If you're new to stock investing, here's how to buy Trevi Therapeutics stock.

What is TRVI's revenue growth forecast for 2026-2028?

(NASDAQ: TRVI) Trevi Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Trevi Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast TRVI's revenue for 2026 to be $354,800,059, with the lowest TRVI revenue forecast at $302,735,133, and the highest TRVI revenue forecast at $406,864,985. On average, 4 Wall Street analysts forecast TRVI's revenue for 2027 to be $2,186,382,095, with the lowest TRVI revenue forecast at $296,528,718, and the highest TRVI revenue forecast at $5,256,143,929.

In 2028, TRVI is forecast to generate $6,901,188,713 in revenue, with the lowest revenue forecast at $3,089,415,482 and the highest revenue forecast at $11,668,060,256.

What is TRVI's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: TRVI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is TRVI's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TRVI price target, the average TRVI price target is $8.50, with the highest TRVI stock price forecast at $9.00 and the lowest TRVI stock price forecast at $8.00.

On average, Wall Street analysts predict that Trevi Therapeutics's share price could reach $8.50 by Apr 9, 2025. The average Trevi Therapeutics stock price prediction forecasts a potential upside of 220.75% from the current TRVI share price of $2.65.

What is TRVI's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: TRVI) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.